A bicarbonate/lactate peritoneal dialysis solution (Bic/Lac) has been developed based on in vitro and ex vivo data showing better preservation of cell function and correction of pain on infusion.
Design
This was a randomized, prospective, controlled, open-label study comparing a new 25 mmol/L bicarbonate/15 mmol/L lactate with a standard 40 mmol/L lactate-buffered peritoneal dialysis solution (Lac) over a 12-month treatment period.
Dialysis adequacy and peritoneal equilibration test (PET, week –4, months 3, 6, and 12); 24-hour ultrafiltration (week –4, months 1, 3, and 6); blood biochemistry (week –2, day 0, months 1, 2, 3,6, 9, and 12); and a product acceptability questionnaire (months 1 and 6).
Results
88 patients completed the first 6 months, and 44 the full year. The solutions were shown to be therapeutically equivalent with respect to plasma bicarbonate and peritoneal urea and creatinine clearances. Ultrafiltration in the Bic/Lac group increased significantly from baseline by about 150 mL/day for the whole of the 6-month treatment period (p < 0.05). The biochemistry profile, adverse events, and physical examination (except body weight where there was a statistically significant increase in the Bic/Lac group) results did not differ significantly between the two groups. Reduced pain/discomfort on infusion or an increased sense of well-being was reported by 41% of patients on the Bic/Lac fluid.
Conclusions
The Bic/Lac solution is safe and effective in correcting uremic acidosis, provides relief of inflow pain/discomfort, and improves ultrafiltration and body weight.
FerianiM., DissegnaD., La GrecaG., Passlick–DeetjenJ.Short term clinical study with bicarbonate-containing peritoneal dialysis solution.Perit Dial Int1993; 13: 296–301.
2.
ColesG.A., GokalR., OggC., JaniF., O'DonoghueD.J., CancariniG.C.A randomized controlled trial of a bicarbonate- and a bicarbonate/lactate-containing dialysis solution in CAPD.Perit Dial Int1997; 17: 48–51.
3.
ColesG.A., O'DonoghueD.J., PritchardN., OggC.S., JaniF.M., GokalR.A controlled trial of two bicarbonate-containing dialysis fluids for CAPD — final report.Nephrol Dial Transplant1998; 13: 3165–71.
4.
SchambyeH.T., PedersenF.B., WangP.Bicarbonate is not the ultimate answer to the biocompatibility problems of CAPD solutions: A cytotoxicity test of CAPD solutions and effluents.Adv Perit Dial1992; 20: 41–6.
5.
SchambyeH.T., PedersenF.B., ChristensenH.K., BerthelsenH., WangP.The cytotoxicity of continuous ambulatory peritoneal dialysis solutions with different bicarbonate/lactate ratios.Perit Dial Int1993; 13(Suppl): S116–18.
6.
MackenzieR.K., HolmesC.J., MoseleyA., JenkinsJ.P., WilliamsJ.D., ColesG.A.Bicarbonate/lactate- and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNFalpha secretion.J Am Soc Nephrol1998; 9: 1499–506.
7.
MactierR.A., SprosenT.S., GokalR., WilliamsP.F., LindberghM., NaikR.B.Bicarbonate and bicarbonate/lactate PD solutions for the treatment of infusion pain.Kidney Int1998; 53: 1061–7.
8.
ICH Guidelines for good clinical practice.London: The European Agency for the Evaluation of Medical Products. Document number CPMP/ICH/135/95*, including post step 4 errata.
9.
TwardowskiZ.J.Clinical value of standardised equilibration tests in CAPD patients. Current concepts of CAPD.Blood Purif1989; 7: 95–108.
10.
Siggaard–AndersenO.The acid-base status of the blood.4th ed.Copenhagen: Munksgaard, 1976.
11.
GrahamK.A., ReaichD., ChannonS.M., DownieS., GilmourE., Passlick–DeetjenJ.Correction of acidosis in CAPD decreases whole body protein degradation.Kidney Int1996; 49: 1396–400.
12.
SteinA., MoorhouseJ., Iles–SmithH., BakerF., JohnstoneJ., JamesG.Role of an improvement in acid-base status and nutrition in CAPD patients.Kidney Int1997; 52: 1089–95.
13.
FerianiM.Adequacy of acid-base correction in continuous ambulatory peritoneal dialysis patients.Perit Dial Int1994; 14(Suppl 3): S133–8.
14.
WallsJ.Metabolic acidosis and uremia.Perit Dial Int1995; 15(5 Suppl): S36–8.
15.
HutchisonA.J., FreemontA.J., BoultonH.F., GokalR.Low calcium dialysis fluid and oral calcium carbonate in CAPD. A method of controlling hyperphosphataemia whilst minimising aluminium exposure and hypercalcaemia.Nephrol Dial Transplant1992; 7: 1219–25.
RippeB., SimonsenO., WieslanderA., LandgrenC.Clinical and physiological effects of a new, less toxic and less acidic fluid for peritoneal dialysis.Perit Dial Int1997; 17: 27–34.
18.
ParkM.S., HeimbürgerO., WaniewskiJ., WerynskiJ., WerynskiA., LeeH.B.The effect of dialysate acidity on peritoneal solute transport in the rat.Perit Dial Int1995; 15: 312–19.
19.
FerianiM., KirchgessnerJ., La GrecaG., Passlick–DeetjenJ., and the Bicarbonate CAPD Cooperative Group. Randomized long-term evaluation of bicarbonate-buffered CAPD solution.Kidney Int1998; 54: 1731–8.
20.
YatzidisH.Enhanced ultrafiltration in rabbits with bicarbonate glycylglycine peritoneal dialysis solution.Perit Dial Int1993; 13: 302–6.
21.
YamamotoT., SakakuraT., YamakawaM., HoriuchiN., HirataS., IritaniY.Clinical effects of long term use of neutralised dialysate for continuous ambulatory peritoneal dialysis.Nephron1992; 60: 324–9.
22.
SelgasR., BajoM-A, Fernandez-ReyesM-J, JimenezC., Del PesoG., SanchezC.Peritoneal functional changes induced by dialysate containing bicarbonate instead of lactate.Adv Perit Dial1996; 12: 49–52.
23.
ColesG.A.Have we underestimated the importance of fluid balance for the survival of PD patients?Perit Dial Int1997; 17: 321–6.
24.
WilliamsJ.D., HolmesC.J., JonesS., MackenzieR., ColesG.A., FaictD.Long-term in vivo exposure to bicarbonate/lactate dialysis fluid improves ex vivo peritoneal macrophage (PMΦ) function (Abstract).Perit Dial Int1998; 18(Suppl 2): S83.
25.
CookerL.A., LunebergP., FaictD., ChooC., HolmesC.J.Reduced glucose degradation products in bicarbonate/ lactate-buffered peritoneal dialysis solutions produced in two-chambered bags.Perit Dial Int1997; 17: 373–8.
26.
DawnayA., WieslanderA., MillarD.J.In vitro advanced glycation end-product formation reduced in PD fluid heat sterilized in two-compartment bags (Abstract).J Am Soc Nephrol1996; 7: 1477.
27.
HondaK., NittaK., HoritaS., YumuraW., NiheiH., NagaiR.Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultrafiltration.Nephrol Dial Transplant1999; 14: 1541–9.
28.
DuweA.K., VasS.I., WeatherheadJ.W.Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis and bactericidal activity in vitro.Infect Immun1981; 33: 130–5.
29.
TopleyN., AlobaidiH.M.M., DaviesM., ColesG.A., WilliamsJ.D., LloydD.The effect of dialysate on peritoneal phagocyte oxidative metabolism.Kidney Int1988; 34: 404–11.
30.
IngB.L., GuptaD.K., NowabS.M., ZhouF-Q, RahmanM.A., DaugirdasJ.T.Suppression of neutrophil superoxide production by conventional peritoneal dialysis solution.Int J Artif Organs1988; 11: 351–4.
31.
JörresA., JörresD., GahlG.M., KesselM., MüllerL., KöttgenE.Leukotriene B4 and tumor necrosis factor release from leukocytes: Effect of peritoneal dialysate.Nephron1991; 58: 276–82.
32.
Van BronswijkH., VerbrughH.A., BosH.J., HeeziusECJM, OeP.L., van der MeulenJ.Cytotoxic effects of commercial continuous ambulatory peritoneal dialysis (CAPD) fluids and of bacterial exoproducts on human mesothelial cells in vitro.Perit Dial Int1989; 9: 197–202.
33.
WitowskiJ., TopleyN., JörresA., LiberekT., ColesG.A., WilliamsJ.D.Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis.Kidney Int1995; 47: 282–93.
34.
De FijterC.W.H., VerbrughH.A., PetersE.D.J., OeP.L., van der MeulenJ., VerhoefJ.In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD.Clin Nephrol1993; 39: 75–80.
35.
VerbrughH.A., KeaneW.F., ConroyW.E., PetersonP.K.Bacterial growth and killing in chronic ambulatory peritoneal dialysis fluids.J Clin Microbiol1984; 20: 199–203.
